T. Rowe Price Associates
GLUE icon

T. Rowe Price Associates’s Monte Rosa Therapeutics GLUE Stock Holding History

T. Rowe Price Associates’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214M Buy
8,861,171
+2,140,983
+32% +$40.5M 0.02% 492
2026
Q1 		$111M Buy
6,720,188
+1,601,284
+31% +$30.6M 0.01% 590
2025
Q4 		$80.3M Buy
5,118,904
+481,844
+10% +$6.49M 0.01% 682
2025
Q3 		$34.4M Sell
4,637,060
-1,688,598
-27% -$8.94M ﹤0.01% 908
2025
Q2 		$28.5M Sell
6,325,658
-318,478
-5% -$1.42M ﹤0.01% 880
2025
Q1 		$30.8M Sell
6,644,136
-472,501
-7% -$2.9M ﹤0.01% 852
2024
Q4 		$49.4M Buy
7,116,637
+515,496
+8% +$3.87M 0.01% 760
2024
Q3 		$35M Buy
6,601,141
+623,554
+10% +$3.15M ﹤0.01% 853
2024
Q2 		$22.4M Buy
5,977,587
+880,800
+17% +$4.49M ﹤0.01% 934
2024
Q1 		$35.9M Buy
5,096,787
+155,880
+3% +$924K ﹤0.01% 816
2023
Q4 		$27.9M Buy
4,940,907
+1,070,360
+28% +$4.2M ﹤0.01% 865
2023
Q3 		$18.5M Sell
3,870,547
-25,951
-0.7% -$167K ﹤0.01% 935
2023
Q2 		$26.7M Buy
3,896,498
+203,004
+5% +$1.31M ﹤0.01% 858
2023
Q1 		$28.8M Buy
3,693,494
+10,064
+0.3% +$70K ﹤0.01% 827
2022
Q4 		$28M Sell
3,683,430
-79,956
-2% -$666K ﹤0.01% 826
2022
Q3 		$30.7M Sell
3,763,386
-1,485,749
-28% -$13.6M 0.01% 778
2022
Q2 		$50.8M Sell
5,249,135
-101,788
-2% -$1.02M 0.01% 868
2022
Q1 		$75M Buy
5,350,923
+1,204,004
+29% +$16.7M 0.01% 827
2021
Q4 		$84.7M Buy
4,146,919
+999,985
+32% +$20.9M 0.01% 817
2021
Q3 		$69.3M Buy
3,146,934
+409,280
+15% +$11.7M 0.01% 900
2021
Q2 		$61.3M Buy
+2,737,654
New +$55.8M 0.01% 963

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return

T. Rowe Price Associates's GLUE Position: Q2 2026 in Review

T. Rowe Price Associates increased its Monte Rosa Therapeutics (GLUE) stake by 32% in Q2 2026, buying an estimated $40.5M and bringing the position to 8,861,171 shares worth $214M. The position accounts for 0.02% of the portfolio, ranked #492.

T. Rowe Price Associates first reported a position in GLUE in Q2 2021 and has held it in 21 quarters since. 193 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • T. Rowe Price Associates held 8,861,171 shares of Monte Rosa Therapeutics worth $214M as of Q2 2026.
  • T. Rowe Price Associates bought 2,140,983 Monte Rosa Therapeutics shares in Q2 2026, an estimated $40.5M.
  • Monte Rosa Therapeutics made up 0.02% of T. Rowe Price Associates's portfolio in Q2 2026, its #492 holding.
  • T. Rowe Price Associates first reported a position in Monte Rosa Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 193 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.